Review



anti mouse cd11b ly6c fcgr4 nk1 1 ly6g siglec f mab  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 98

    Structured Review

    Miltenyi Biotec anti mouse cd11b ly6c fcgr4 nk1 1 ly6g siglec f mab
    Anti Mouse Cd11b Ly6c Fcgr4 Nk1 1 Ly6g Siglec F Mab, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 98/100, based on 26 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11b+ly6c/CD11b%2Fc+Antibody%2C+anti-rat%2C+REAfinity/pm37462944-277-17-8
    Average 98 stars, based on 26 article reviews
    anti mouse cd11b ly6c fcgr4 nk1 1 ly6g siglec f mab - by Bioz Stars, 2026-09
    98/100 stars

    Images

    Related Articles

    Selection:

    Article Title: Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity
    Article Snippet: For intracellular stains, cells were fixed and permeabilized using the FoxP3 Staining Buffer kit (ThermoFisher). .. For experiments that required the sorting of CD11b + Ly6C + , CD4 + , or CD8 + T cells, TILs were filtered through 70 μm nylon mesh followed by a CD45 + positive selection using a CD45 (TIL) Microbeads kit (Miltenyi Biotec) and an autoMACS Pro Separator (Miltenyi Biotec). .. Where indicated, cells were sorted on a FACSAria II Cell Sorter (BD Biosciences) into 1.7 ml tubes containing 400 μl cRPMI.

    Flow Cytometry:

    Article Title: Loss of myeloid‐specific lamin A/C drives lung metastasis through Gfi‐1 and C/EBPε‐mediated granulocytic differentiation
    Article Snippet: After hemolysis for 10 minutes at 4°C, cells were labeled with fluorescence‐conjugated antibodies including CD3 (145‐2c11, 1:100; BD Biosciences), CD4 (GK1.5, 1:100; BD Biosciences), CD8 (53‐6.7, 1:100; BD Biosciences), CD19 (1D3, 1:100; BD Biosciences), CD45R/B220 (RA3‐6B2, 1:100; BD Biosciences), CD11b (M1/70, 1:100; BD Biosciences), Ly6C (AL‐21, 1:200; BD Biosciences), Ly6G (1A8, 1:100; BD Biosciences), lineage cocktail (558074; BD Biosciences), CD117 (2B8, 1:100; BD Biosciences), ScaI (E13‐161.7, 1:100; Biolegend), CD34 (RAM34, 1:50; BD Biosciences), Sytox blue nucleic acid stain (S11348, 1:2000; Thermo Fisher Scientific), and 7‐AAD (BD Biosciences), and analyzed on a FACS Calibur, Canto II or LSR II flow cytometer. .. For sorting, CD3 + CD4 + or CD3 + CD8 + T cells, CD19 + B220 + B cells, Gr‐1 + CD11b + , CD11b + Ly6C + ‐ or CD11b + Ly6G + ‐myeloid cells, or Lin − CD117 + ScaI − CD34 + progenitor cells were sorted by the FACSAria flow cytometer (BD Biosciences) or magnetically activated cell sorting with Ly6G, and Ly6C microbeads per the manufacturer's protocol (Miltenyi Biotec). .. HS/PCs were enriched by using immunomagnetic column (Stem Cell Technologies).

    Article Title: miR-130a and miR-145 reprogram Gr-1 + CD11b + myeloid cells and inhibit tumor metastasis through improved host immunity
    Article Snippet: Cells were labeled with fluorescence-conjugated antibodies: CD3 (145-2c11, BD Biosciences 1:100), CD4 (GK1.5, BD Biosciences 1:100), CD8 (53-6.7, BD Biosciences 1:100), CD19 (1D3, BD Biosciences 1:100), Gr-1 (RB6-8C5, 1:100), CD11b (M1/70, BD Biosciences 1:100), Ly6C (AL-21, BD Biosciences 1:200), Ly6G (1A8, BD Biosciences 1:100), IFNγ (XMG1.2, BD Biosciences 1:100), CD117 (2B8, BD Biosciences 1:100), ScaI (E13-161.7, Biolegend 1:100), HLA-DR (TU36, BD Biosciences 1:100), CD14 (MφP9, BD Biosciences 1:100), CD15 (W6D3, BD Biosciences 1:100), Sytox blue (S34857, Thermo Fisher Scientific 1:2000), CFSE (C34554, Thermo Fisher Scientific 1:100) and 7-AAD (00-6993-50, BD Biosciences 1:1000) and analyzed on a FACS Calibur, Canto II or LSR II flow cytometer (BD Biosciences). .. For sorting, CD3 + CD4 + or CD3 + CD8 + T cells, CD3 – CD19 + B cells, and Gr-1 + CD11b + , CD11b + Ly6C + or CD11b + Ly6G + myeloid cells, or GFP + or GFP – Gr-1 + CD11b + myeloid cells were sorted by the FACSAria flow cytometer (BD Biosciences) or magnetically activated cell sorting (MACS) with CD11b and Gr-1 microbeads per the manufacturer’s protocol (Miltenyi Biotec). ..

    FACS:

    Article Title: Loss of myeloid‐specific lamin A/C drives lung metastasis through Gfi‐1 and C/EBPε‐mediated granulocytic differentiation
    Article Snippet: After hemolysis for 10 minutes at 4°C, cells were labeled with fluorescence‐conjugated antibodies including CD3 (145‐2c11, 1:100; BD Biosciences), CD4 (GK1.5, 1:100; BD Biosciences), CD8 (53‐6.7, 1:100; BD Biosciences), CD19 (1D3, 1:100; BD Biosciences), CD45R/B220 (RA3‐6B2, 1:100; BD Biosciences), CD11b (M1/70, 1:100; BD Biosciences), Ly6C (AL‐21, 1:200; BD Biosciences), Ly6G (1A8, 1:100; BD Biosciences), lineage cocktail (558074; BD Biosciences), CD117 (2B8, 1:100; BD Biosciences), ScaI (E13‐161.7, 1:100; Biolegend), CD34 (RAM34, 1:50; BD Biosciences), Sytox blue nucleic acid stain (S11348, 1:2000; Thermo Fisher Scientific), and 7‐AAD (BD Biosciences), and analyzed on a FACS Calibur, Canto II or LSR II flow cytometer. .. For sorting, CD3 + CD4 + or CD3 + CD8 + T cells, CD19 + B220 + B cells, Gr‐1 + CD11b + , CD11b + Ly6C + ‐ or CD11b + Ly6G + ‐myeloid cells, or Lin − CD117 + ScaI − CD34 + progenitor cells were sorted by the FACSAria flow cytometer (BD Biosciences) or magnetically activated cell sorting with Ly6G, and Ly6C microbeads per the manufacturer's protocol (Miltenyi Biotec). .. HS/PCs were enriched by using immunomagnetic column (Stem Cell Technologies).

    Article Title: miR-130a and miR-145 reprogram Gr-1 + CD11b + myeloid cells and inhibit tumor metastasis through improved host immunity
    Article Snippet: Cells were labeled with fluorescence-conjugated antibodies: CD3 (145-2c11, BD Biosciences 1:100), CD4 (GK1.5, BD Biosciences 1:100), CD8 (53-6.7, BD Biosciences 1:100), CD19 (1D3, BD Biosciences 1:100), Gr-1 (RB6-8C5, 1:100), CD11b (M1/70, BD Biosciences 1:100), Ly6C (AL-21, BD Biosciences 1:200), Ly6G (1A8, BD Biosciences 1:100), IFNγ (XMG1.2, BD Biosciences 1:100), CD117 (2B8, BD Biosciences 1:100), ScaI (E13-161.7, Biolegend 1:100), HLA-DR (TU36, BD Biosciences 1:100), CD14 (MφP9, BD Biosciences 1:100), CD15 (W6D3, BD Biosciences 1:100), Sytox blue (S34857, Thermo Fisher Scientific 1:2000), CFSE (C34554, Thermo Fisher Scientific 1:100) and 7-AAD (00-6993-50, BD Biosciences 1:1000) and analyzed on a FACS Calibur, Canto II or LSR II flow cytometer (BD Biosciences). .. For sorting, CD3 + CD4 + or CD3 + CD8 + T cells, CD3 – CD19 + B cells, and Gr-1 + CD11b + , CD11b + Ly6C + or CD11b + Ly6G + myeloid cells, or GFP + or GFP – Gr-1 + CD11b + myeloid cells were sorted by the FACSAria flow cytometer (BD Biosciences) or magnetically activated cell sorting (MACS) with CD11b and Gr-1 microbeads per the manufacturer’s protocol (Miltenyi Biotec). ..

    Magnetic Cell Separation:

    Article Title: miR-130a and miR-145 reprogram Gr-1 + CD11b + myeloid cells and inhibit tumor metastasis through improved host immunity
    Article Snippet: Cells were labeled with fluorescence-conjugated antibodies: CD3 (145-2c11, BD Biosciences 1:100), CD4 (GK1.5, BD Biosciences 1:100), CD8 (53-6.7, BD Biosciences 1:100), CD19 (1D3, BD Biosciences 1:100), Gr-1 (RB6-8C5, 1:100), CD11b (M1/70, BD Biosciences 1:100), Ly6C (AL-21, BD Biosciences 1:200), Ly6G (1A8, BD Biosciences 1:100), IFNγ (XMG1.2, BD Biosciences 1:100), CD117 (2B8, BD Biosciences 1:100), ScaI (E13-161.7, Biolegend 1:100), HLA-DR (TU36, BD Biosciences 1:100), CD14 (MφP9, BD Biosciences 1:100), CD15 (W6D3, BD Biosciences 1:100), Sytox blue (S34857, Thermo Fisher Scientific 1:2000), CFSE (C34554, Thermo Fisher Scientific 1:100) and 7-AAD (00-6993-50, BD Biosciences 1:1000) and analyzed on a FACS Calibur, Canto II or LSR II flow cytometer (BD Biosciences). .. For sorting, CD3 + CD4 + or CD3 + CD8 + T cells, CD3 – CD19 + B cells, and Gr-1 + CD11b + , CD11b + Ly6C + or CD11b + Ly6G + myeloid cells, or GFP + or GFP – Gr-1 + CD11b + myeloid cells were sorted by the FACSAria flow cytometer (BD Biosciences) or magnetically activated cell sorting (MACS) with CD11b and Gr-1 microbeads per the manufacturer’s protocol (Miltenyi Biotec). ..



    Similar Products

    98
    Miltenyi Biotec anti mouse cd11b ly6c fcgr4 nk1 1 ly6g siglec f mab
    Anti Mouse Cd11b Ly6c Fcgr4 Nk1 1 Ly6g Siglec F Mab, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11b+ly6c/CD11b%2Fc+Antibody%2C+anti-rat%2C+REAfinity/pm37462944-277-17-8
    Average 98 stars, based on 1 article reviews
    anti mouse cd11b ly6c fcgr4 nk1 1 ly6g siglec f mab - by Bioz Stars, 2026-09
    98/100 stars
      Buy from Supplier

    90
    Thermo Fisher abs against cd11b, ly6c, ly6g, cd4, cd25, and foxp3 antibody
    Abs Against Cd11b, Ly6c, Ly6g, Cd4, Cd25, And Foxp3 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11b+ly6c/fluorochrome+conjugated+abs/pm40521204-83-14-17
    Average 90 stars, based on 1 article reviews
    abs against cd11b, ly6c, ly6g, cd4, cd25, and foxp3 antibody - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    94
    Bio-Rad cd11b m1 70 anti mouse ly6g anti mouse ly6g 1a8 anti mouse ly6c anti mouse ly6g 1a8 anti mouse ly6c hk1 4 anti mouse f4 80
    Cd11b M1 70 Anti Mouse Ly6g Anti Mouse Ly6g 1a8 Anti Mouse Ly6c Anti Mouse Ly6g 1a8 Anti Mouse Ly6c Hk1 4 Anti Mouse F4 80, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11b+ly6c/Mouse+anti+Rabbit+CD11b/pmc12084582__41467_2025_59393_MOESM1_ESM-468-36-53
    Average 94 stars, based on 1 article reviews
    cd11b m1 70 anti mouse ly6g anti mouse ly6g 1a8 anti mouse ly6c anti mouse ly6g 1a8 anti mouse ly6c hk1 4 anti mouse f4 80 - by Bioz Stars, 2026-09
    94/100 stars
      Buy from Supplier

    90
    Becton Dickinson lineage (cd3e, cd11b, cd45r/b220, ly76, ly6g ly6c
    Lineage (Cd3e, Cd11b, Cd45r/B220, Ly76, Ly6g Ly6c, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11b+ly6c/biotin+mouse+lineage+panel/pm39029138-110-38-47
    Average 90 stars, based on 1 article reviews
    lineage (cd3e, cd11b, cd45r/b220, ly76, ly6g ly6c - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Servicebio Inc cd11b, ly6c, and ly6g staining assays
    CCR1 + -G-MDSCs accumulate to SMAD4-deficient CRC tissues via the CCL15/CCR1 axis and CCL9/CCR1 axis in clinical specimens and mouse models. (A) Clinical specimens of human CRC were examined using immunohistochemistry staining for SMAD4, CCR1 and CD33, and (B) representative images of indicated specimens. Scale bar = 100 μm. (C) Immunohistochemistry analysis of human CRC specimens showing the correlations of SMAD4 and CCR1 expression. Pearson correlation analysis was used to indicate correlation. (D) Fluorescence Activated Cell Sorter (FACS) analysis of the percent of MDSCs in PBMC from healthy subjects and clinical patients with CRC. (E) Representative FACS plots of CD33 + CCR1 + in CD11b + HLA-DR – cells. (F) Quantification of CCL15 concentration in plasma from healthy subjects and clinical patients with CRC. (G) Representative FACS plots and (H) quantification of the percent of CD14 – CD15 + (G-MDSCs) in MDSCs, respectively. G: G-MDSCs, M: MDSCs. (I) MC38 or CT26 cells were injected into spleens of C57BL/6 or BALB/c mice respectively. Mice were reared for 14 days and sacrificed for analysis of liver metastasis, n = 4. (J) Representative FACS plots of MDSCs in CD11b + , CCR1 + in MDSCs from MC38 and CT26 metastasis tissues, respectively. (K) Liver metastasis from mice was stained for CD11b (green) and <t>Ly6G/Ly6C</t> (red). Inset shows invasion front of liver metastasis. Scale bar = 100 μm, scale bar for zoom out = 30 μm. (L) Quantification of the percent of G-MDSCs in CD11b + , n = 4, from MC38 and CT26 metastasis tissues, respectively. (M) Immunohistochemistry staining for CCL9 and CCR1 from MC38 and CT26 metastasis tissues, Scale bar = 100 μm, scale bar for zoom out = 20 μm. (N) Quantification of CCL9 concentration in tumors, n = 4. (O) Schematic summary showing SMAD4-deficient CRC recruited CCR1 + -G-MDSC via the CCL9/CCR1 axis. Data are presented as mean ± SD of at least two independent experiments. Two-tailed unpaired Student's t -test (H, L, N), and Brown-Forsythe and Welch ANOVA tests were used (D, F) for statistical analysis with calculated P values shown.
    Cd11b, Ly6c, And Ly6g Staining Assays, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11b+ly6c/anti+cd11b+antibody/pmc11365421-154-1-9
    Average 90 stars, based on 1 article reviews
    cd11b, ly6c, and ly6g staining assays - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    95
    Bio X Cell cd11b
    CCR1 + -G-MDSCs accumulate to SMAD4-deficient CRC tissues via the CCL15/CCR1 axis and CCL9/CCR1 axis in clinical specimens and mouse models. (A) Clinical specimens of human CRC were examined using immunohistochemistry staining for SMAD4, CCR1 and CD33, and (B) representative images of indicated specimens. Scale bar = 100 μm. (C) Immunohistochemistry analysis of human CRC specimens showing the correlations of SMAD4 and CCR1 expression. Pearson correlation analysis was used to indicate correlation. (D) Fluorescence Activated Cell Sorter (FACS) analysis of the percent of MDSCs in PBMC from healthy subjects and clinical patients with CRC. (E) Representative FACS plots of CD33 + CCR1 + in CD11b + HLA-DR – cells. (F) Quantification of CCL15 concentration in plasma from healthy subjects and clinical patients with CRC. (G) Representative FACS plots and (H) quantification of the percent of CD14 – CD15 + (G-MDSCs) in MDSCs, respectively. G: G-MDSCs, M: MDSCs. (I) MC38 or CT26 cells were injected into spleens of C57BL/6 or BALB/c mice respectively. Mice were reared for 14 days and sacrificed for analysis of liver metastasis, n = 4. (J) Representative FACS plots of MDSCs in CD11b + , CCR1 + in MDSCs from MC38 and CT26 metastasis tissues, respectively. (K) Liver metastasis from mice was stained for CD11b (green) and <t>Ly6G/Ly6C</t> (red). Inset shows invasion front of liver metastasis. Scale bar = 100 μm, scale bar for zoom out = 30 μm. (L) Quantification of the percent of G-MDSCs in CD11b + , n = 4, from MC38 and CT26 metastasis tissues, respectively. (M) Immunohistochemistry staining for CCL9 and CCR1 from MC38 and CT26 metastasis tissues, Scale bar = 100 μm, scale bar for zoom out = 20 μm. (N) Quantification of CCL9 concentration in tumors, n = 4. (O) Schematic summary showing SMAD4-deficient CRC recruited CCR1 + -G-MDSC via the CCL9/CCR1 axis. Data are presented as mean ± SD of at least two independent experiments. Two-tailed unpaired Student's t -test (H, L, N), and Brown-Forsythe and Welch ANOVA tests were used (D, F) for statistical analysis with calculated P values shown.
    Cd11b, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11b+ly6c/InVivoPlus+anti-mouse+Ly6G+Ly6C/pm38704109-61-74-83
    Average 95 stars, based on 1 article reviews
    cd11b - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    90
    Taconic Biosciences model flow analysis of monocytes (ly6c+cd11b)
    CCR1 + -G-MDSCs accumulate to SMAD4-deficient CRC tissues via the CCL15/CCR1 axis and CCL9/CCR1 axis in clinical specimens and mouse models. (A) Clinical specimens of human CRC were examined using immunohistochemistry staining for SMAD4, CCR1 and CD33, and (B) representative images of indicated specimens. Scale bar = 100 μm. (C) Immunohistochemistry analysis of human CRC specimens showing the correlations of SMAD4 and CCR1 expression. Pearson correlation analysis was used to indicate correlation. (D) Fluorescence Activated Cell Sorter (FACS) analysis of the percent of MDSCs in PBMC from healthy subjects and clinical patients with CRC. (E) Representative FACS plots of CD33 + CCR1 + in CD11b + HLA-DR – cells. (F) Quantification of CCL15 concentration in plasma from healthy subjects and clinical patients with CRC. (G) Representative FACS plots and (H) quantification of the percent of CD14 – CD15 + (G-MDSCs) in MDSCs, respectively. G: G-MDSCs, M: MDSCs. (I) MC38 or CT26 cells were injected into spleens of C57BL/6 or BALB/c mice respectively. Mice were reared for 14 days and sacrificed for analysis of liver metastasis, n = 4. (J) Representative FACS plots of MDSCs in CD11b + , CCR1 + in MDSCs from MC38 and CT26 metastasis tissues, respectively. (K) Liver metastasis from mice was stained for CD11b (green) and <t>Ly6G/Ly6C</t> (red). Inset shows invasion front of liver metastasis. Scale bar = 100 μm, scale bar for zoom out = 30 μm. (L) Quantification of the percent of G-MDSCs in CD11b + , n = 4, from MC38 and CT26 metastasis tissues, respectively. (M) Immunohistochemistry staining for CCL9 and CCR1 from MC38 and CT26 metastasis tissues, Scale bar = 100 μm, scale bar for zoom out = 20 μm. (N) Quantification of CCL9 concentration in tumors, n = 4. (O) Schematic summary showing SMAD4-deficient CRC recruited CCR1 + -G-MDSC via the CCL9/CCR1 axis. Data are presented as mean ± SD of at least two independent experiments. Two-tailed unpaired Student's t -test (H, L, N), and Brown-Forsythe and Welch ANOVA tests were used (D, F) for statistical analysis with calculated P values shown.
    Model Flow Analysis Of Monocytes (Ly6c+Cd11b), supplied by Taconic Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11b+ly6c/model+flow+analysis+of+monocytes++ly6c+cd11b+/pmc10808415__DataSheet_1-20-5-0
    Average 90 stars, based on 1 article reviews
    model flow analysis of monocytes (ly6c+cd11b) - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Galectin Therapeutics polymorphonucleate mdsc (pm-mdsc (cd11b+/ly6c+/mild, ly6g+/galectin low)
    List of antibodies used to characterize the TIME (membrane staining)
    Polymorphonucleate Mdsc (Pm Mdsc (Cd11b+/Ly6c+/Mild, Ly6g+/Galectin Low), supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11b+ly6c/cd11b+++gr+1+++cells/pmc10694585-481-13-17
    Average 90 stars, based on 1 article reviews
    polymorphonucleate mdsc (pm-mdsc (cd11b+/ly6c+/mild, ly6g+/galectin low) - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Galectin Therapeutics monocytic mdsc (m-mdsc (cd11b+/ly6c+/ly6g-/galectin)
    List of antibodies used to characterize the TIME (membrane staining)
    Monocytic Mdsc (M Mdsc (Cd11b+/Ly6c+/Ly6g /Galectin), supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11b+ly6c/cd11b+++gr+1+++cells/pmc10694585-481-9-12
    Average 90 stars, based on 1 article reviews
    monocytic mdsc (m-mdsc (cd11b+/ly6c+/ly6g-/galectin) - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Galectin Therapeutics m-mdsc (cd11b+/ly6c+/ly6g-/galectin)
    List of antibodies used to characterize the TIME (membrane staining)
    M Mdsc (Cd11b+/Ly6c+/Ly6g /Galectin), supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd11b+ly6c/cd11b+++gr+1+++cells/pm37979181-370-9-12
    Average 90 stars, based on 1 article reviews
    m-mdsc (cd11b+/ly6c+/ly6g-/galectin) - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    Image Search Results


    CCR1 + -G-MDSCs accumulate to SMAD4-deficient CRC tissues via the CCL15/CCR1 axis and CCL9/CCR1 axis in clinical specimens and mouse models. (A) Clinical specimens of human CRC were examined using immunohistochemistry staining for SMAD4, CCR1 and CD33, and (B) representative images of indicated specimens. Scale bar = 100 μm. (C) Immunohistochemistry analysis of human CRC specimens showing the correlations of SMAD4 and CCR1 expression. Pearson correlation analysis was used to indicate correlation. (D) Fluorescence Activated Cell Sorter (FACS) analysis of the percent of MDSCs in PBMC from healthy subjects and clinical patients with CRC. (E) Representative FACS plots of CD33 + CCR1 + in CD11b + HLA-DR – cells. (F) Quantification of CCL15 concentration in plasma from healthy subjects and clinical patients with CRC. (G) Representative FACS plots and (H) quantification of the percent of CD14 – CD15 + (G-MDSCs) in MDSCs, respectively. G: G-MDSCs, M: MDSCs. (I) MC38 or CT26 cells were injected into spleens of C57BL/6 or BALB/c mice respectively. Mice were reared for 14 days and sacrificed for analysis of liver metastasis, n = 4. (J) Representative FACS plots of MDSCs in CD11b + , CCR1 + in MDSCs from MC38 and CT26 metastasis tissues, respectively. (K) Liver metastasis from mice was stained for CD11b (green) and Ly6G/Ly6C (red). Inset shows invasion front of liver metastasis. Scale bar = 100 μm, scale bar for zoom out = 30 μm. (L) Quantification of the percent of G-MDSCs in CD11b + , n = 4, from MC38 and CT26 metastasis tissues, respectively. (M) Immunohistochemistry staining for CCL9 and CCR1 from MC38 and CT26 metastasis tissues, Scale bar = 100 μm, scale bar for zoom out = 20 μm. (N) Quantification of CCL9 concentration in tumors, n = 4. (O) Schematic summary showing SMAD4-deficient CRC recruited CCR1 + -G-MDSC via the CCL9/CCR1 axis. Data are presented as mean ± SD of at least two independent experiments. Two-tailed unpaired Student's t -test (H, L, N), and Brown-Forsythe and Welch ANOVA tests were used (D, F) for statistical analysis with calculated P values shown.

    Journal: Acta Pharmaceutica Sinica. B

    Article Title: CCL9/CCR1 axis-driven chemotactic nanovesicles for attenuating metastasis of SMAD4-deficient colorectal cancer by trapping TGF- β

    doi: 10.1016/j.apsb.2024.05.009

    Figure Lengend Snippet: CCR1 + -G-MDSCs accumulate to SMAD4-deficient CRC tissues via the CCL15/CCR1 axis and CCL9/CCR1 axis in clinical specimens and mouse models. (A) Clinical specimens of human CRC were examined using immunohistochemistry staining for SMAD4, CCR1 and CD33, and (B) representative images of indicated specimens. Scale bar = 100 μm. (C) Immunohistochemistry analysis of human CRC specimens showing the correlations of SMAD4 and CCR1 expression. Pearson correlation analysis was used to indicate correlation. (D) Fluorescence Activated Cell Sorter (FACS) analysis of the percent of MDSCs in PBMC from healthy subjects and clinical patients with CRC. (E) Representative FACS plots of CD33 + CCR1 + in CD11b + HLA-DR – cells. (F) Quantification of CCL15 concentration in plasma from healthy subjects and clinical patients with CRC. (G) Representative FACS plots and (H) quantification of the percent of CD14 – CD15 + (G-MDSCs) in MDSCs, respectively. G: G-MDSCs, M: MDSCs. (I) MC38 or CT26 cells were injected into spleens of C57BL/6 or BALB/c mice respectively. Mice were reared for 14 days and sacrificed for analysis of liver metastasis, n = 4. (J) Representative FACS plots of MDSCs in CD11b + , CCR1 + in MDSCs from MC38 and CT26 metastasis tissues, respectively. (K) Liver metastasis from mice was stained for CD11b (green) and Ly6G/Ly6C (red). Inset shows invasion front of liver metastasis. Scale bar = 100 μm, scale bar for zoom out = 30 μm. (L) Quantification of the percent of G-MDSCs in CD11b + , n = 4, from MC38 and CT26 metastasis tissues, respectively. (M) Immunohistochemistry staining for CCL9 and CCR1 from MC38 and CT26 metastasis tissues, Scale bar = 100 μm, scale bar for zoom out = 20 μm. (N) Quantification of CCL9 concentration in tumors, n = 4. (O) Schematic summary showing SMAD4-deficient CRC recruited CCR1 + -G-MDSC via the CCL9/CCR1 axis. Data are presented as mean ± SD of at least two independent experiments. Two-tailed unpaired Student's t -test (H, L, N), and Brown-Forsythe and Welch ANOVA tests were used (D, F) for statistical analysis with calculated P values shown.

    Article Snippet: CD11b, Ly6C, and Ly6G staining assays were served by Servicebio (Hubei Wuhan, China).

    Techniques: Immunohistochemistry, Staining, Expressing, Fluorescence, Concentration Assay, Clinical Proteomics, Injection, Two Tailed Test

    List of antibodies used to characterize the TIME (membrane staining)

    Journal: STAR Protocols

    Article Title: Protocol to characterize the melanoma tumor immune microenvironment in mice from single cell to flow cytometry analysis

    doi: 10.1016/j.xpro.2023.102690

    Figure Lengend Snippet: List of antibodies used to characterize the TIME (membrane staining)

    Article Snippet: In Myeloid Derived Suppressor Cells (MDSCs) we could identify monocytic MDSCs (M-MDSC (CD11b+/Ly6C+/Ly6G-/Galectin+)) polymorphonucleate MDSC (PM-MDSC (CD11b+/Ly6C+/mild, Ly6G+/Galectin low)) ( ).

    Techniques: Membrane, Staining, Concentration Assay, Derivative Assay

    Flow cytometry gating strategy to identify Myeloid Derived Suppressor Cells (MDSCs)

    Journal: STAR Protocols

    Article Title: Protocol to characterize the melanoma tumor immune microenvironment in mice from single cell to flow cytometry analysis

    doi: 10.1016/j.xpro.2023.102690

    Figure Lengend Snippet: Flow cytometry gating strategy to identify Myeloid Derived Suppressor Cells (MDSCs)

    Article Snippet: In Myeloid Derived Suppressor Cells (MDSCs) we could identify monocytic MDSCs (M-MDSC (CD11b+/Ly6C+/Ly6G-/Galectin+)) polymorphonucleate MDSC (PM-MDSC (CD11b+/Ly6C+/mild, Ly6G+/Galectin low)) ( ).

    Techniques: Flow Cytometry, Derivative Assay

    List of antibodies used to characterize the TIME (membrane staining)

    Journal: STAR Protocols

    Article Title: Protocol to characterize the melanoma tumor immune microenvironment in mice from single cell to flow cytometry analysis

    doi: 10.1016/j.xpro.2023.102690

    Figure Lengend Snippet: List of antibodies used to characterize the TIME (membrane staining)

    Article Snippet: In Myeloid Derived Suppressor Cells (MDSCs) we could identify monocytic MDSCs (M-MDSC (CD11b+/Ly6C+/Ly6G-/Galectin+)) polymorphonucleate MDSC (PM-MDSC (CD11b+/Ly6C+/mild, Ly6G+/Galectin low)) ( ).

    Techniques: Membrane, Staining, Concentration Assay, Derivative Assay

    Flow cytometry gating strategy to identify Myeloid Derived Suppressor Cells (MDSCs)

    Journal: STAR Protocols

    Article Title: Protocol to characterize the melanoma tumor immune microenvironment in mice from single cell to flow cytometry analysis

    doi: 10.1016/j.xpro.2023.102690

    Figure Lengend Snippet: Flow cytometry gating strategy to identify Myeloid Derived Suppressor Cells (MDSCs)

    Article Snippet: In Myeloid Derived Suppressor Cells (MDSCs) we could identify monocytic MDSCs (M-MDSC (CD11b+/Ly6C+/Ly6G-/Galectin+)) polymorphonucleate MDSC (PM-MDSC (CD11b+/Ly6C+/mild, Ly6G+/Galectin low)) ( ).

    Techniques: Flow Cytometry, Derivative Assay